The Differentiation Status of Stem Cells and Their Derivatives: A Key Consideration in Transplantation Medicine
Boon Chin Heng,Tong Cao
DOI: https://doi.org/10.1097/01.mat.0000144362.39173.d6
2004-01-01
ASAIO Journal
Abstract:In recent years, both embryonic and adult stem cells have aroused tremendous interest over their potential applications in human regenerative medicine.1–3 A key consideration in stem cell transplantation therapy is the differentiation status of the stem cells being transplanted. This issue has largely been ignored in the majority of transplantation studies in animal models and phase I human clinical trials. The differentiation status of transplanted stem cells or their derivatives is likely to profoundly influence several factors that determine their ability to contribute to tissue/organ regeneration within the recipient. These various factors are summarized in Table 1, and each will be critically examined in turn.Table 1: Comparison of the Transplantation of Undifferentiated Stem Cells vs. Their Differentiated DerivativesIt is a well known fact that undifferentiated human embryonic stem (hES) cells form teratomas upon transplantation into immunologically compromised animal models.4 Teratoma formation obviously would be detrimental to the transplant recipient. Hence, for human clinical therapy, it is imperative that hES cells are differentiated to some degree before transplantation so as to reduce the likelihood of teratoma formation in situ.5,6 Undifferentiated adult stem cells lack the ability to form teratomas but could instead undergo nonspecific multilineage differentiation in vitro.7,8 This is likely to reduce the clinical efficacy of transplantation therapy because only a subfraction of the transplanted stem cells would have differentiated into the required tissue lineage. Further complications may arise from the pathologic state of damaged or diseased tissues/organs providing an “abnormal” milieu for undifferentiated stem cells. The presence of necrotic/apoptotic cells,9 free radicals,10 and inflammatory cytokines11 within the pathologic environment may very well exert an adverse effect on the differentiation pathway of the transplanted stem cells. This could further reduce the proportion of transplanted cells giving rise to the required lineage of interest, as well as result in the formation of undesired tissue lineages at the transplantation site, which could impair tissue/organ regeneration. For example, in the study of Wang et al.,12 the transplantation of undifferentiated mesenchymal stem cells into the pathologic environment of damaged cardiac muscles resulted in the differentiation of some of these cells into fibroblastic scar tissue, which could in turn impair recovery of heart function after myocardial infarction. Undifferentiated stem cells may also lack expression of specific cell surface markers that could facilitate their rapid engraftment and integration within the recipient tissue or organ, i.e., gap junction connexin proteins or surface ligands for interaction with extracellular matrix. Hence, there is a strong likelihood that some degree of differentiation of stem cells in vitro to allow expression of such surface markers may enhance their engraftment efficiency and subsequent integration in situ, thereby improving the clinical efficacy of transplantation therapy. Nevertheless, there are a number of factors that would discourage the use of differentiated stem cell derivatives in transplantation therapy. In the case of autologous adult stem cells, directed differentiation into specific lineages is likely to require prolonged durations of exvivo culture. This would obviously delay treatment to the patient who is likely to be in dire need of therapeutic intervention. There is also evidence that prolonged durations of ex vivo culture could somehow alter the immunogenicity of cultured autologous cells, which may lead to immunorejection upon transplantation.13,14 It can certainly be argued that genetic modulation with recombinant DNA technology could potentially offer a “rapid” and efficient means of directing autologous adult stem cell commitment and differentiation into a required lineage,15,16 without the need for prolonged ex vivo culture. There are, however, overwhelming safety concerns with regard to the application of genetic manipulation in human clinical therapy.17 Differentiated stem cells may also have a reduced proliferative capacity, which could impair their ability to contribute to tissue/organ regeneration. By committing or differentiating stem cells into specific lineages before transplantation, there could be a loss in their ability to give rise to other lineages that might also be beneficial to tissue/organ regeneration, in particular, the vascular endothelial lineage. This is best illustrated by the transplantation of undifferentiated mesenchymal stem cells for the repair of myocardially infarcted hearts. The transplanted stem cells gave rise not only to the cardiomyogenic lineage18 but also to the vascular endothelial lineage.19 The resultant increased angiogenesis appears to play a crucial role in myocardial regeneration.20 Differentiated derivatives of stem cells are also likely to be much more fastidious in their nutritional and oxygen requirement, which could compromise their ability to survive in the adverse pathologic environment of damaged/diseased tissues or organs. This is particularly the case with cell lineages of highly vascularized tissues/organs, such as the myocardium and liver. Indeed, the transplantation of fully differentiated cardiomyocytes and hepatocytes is severely hindered by the ischemic environment present within pathologic heart and liver models, which often leads to an extremely low survival and engraftment rate of the transplanted cells.21,22 Another major factor that would discourage the use of differentiated stem cell derivatives is their higher degree of immunogenicity, in the case of allogenic models of transplantation. It is well established that undifferentiated hES cells have low levels of expression of major histocompatibility complex (MHC) class I and II antigens.23 There is a gradual upregulation in the expression of MHC antigens by hES cells with increased degree of differentiation.23,24 Hence, transplantation of hES derivatives, at early stages of differentiation, would be expected to provoke a much milder immunologic reaction compared with hES derivatives at later stages of differentiation. In the case of undifferentiated bone marrow derived mesenchymal stem cells, these have been reported to be both immunoprivileged25 as well as immunosuppressive,26,27 which would favor the use of these cells in allogenic transplantation. As with ES cells, a gradual upregulation of MHC expression by mesenchymal stem cells with increased degree of differentiation25 has also been reported. Hence, it would appear that a major issue of contention in stem cell transplantation medicine is the choice of transplanting undifferentiated stem cells or their differentiated derivatives. Each of these has advantages and disadvantages. Probably there exists a subtle balance somewhere between the undifferentiated and fully differentiated state, which would be optimal for achieving maximal efficacy of stem cell transplantation therapy. This would be expected to differ for different tissue and organ models of transplantation. At present, this particular aspect of stem cell transplantation has not been well studied. More exhaustive investigations should be carried out in this area of research, in view of its potentially important clinical implications.